Phase 3
N=213
Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for Breakthrough Pain in Patients With Chronic Pain
Chronic Pain
Bottom Line
View on ClinicalTrials.gov: NCT00813488 ↗Enrolled (actual)
213
Serious AEs
2.0%
Results posted
Dec 2010
Primary outcome: Primary: Pain Intensity Difference (PID) at 15 Minutes Post-treatment (PID15) — 0.88; 0.76 Units on scale — p=0.0004
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Fentanyl Buccal Tablet (Drug); Immediate release oxycodone (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Cephalon
- Primary completion
- Nov 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Pain Intensity Difference (PID) at 15 Minutes Post-treatment (PID15) |
0.88; 0.76 | 0.0004 sig |
| SECONDARY Pain Intensity Difference (PID) at 5 Minutes Post-treatment |
.08; .06 | 0.2242 |
| SECONDARY Pain Intensity Difference (PID) at 10 Minutes Post-treatment |
.35; .29 | 0.0106 sig |
| SECONDARY Pain Intensity Difference (PID) at 30 Minutes Post-treatment |
2.10; 1.79 | <0.0001 sig |
| SECONDARY Pain Intensity Difference (PID) at 45 Minutes Post-treatment |
3.13; 2.85 | <0.0001 sig |
| SECONDARY Pain Intensity Difference (PID) at 60 Minutes Post-treatment |
3.65; 3.48 | 0.0002 sig |
| SECONDARY Percentage Change in Pain Intensity Difference (% PID) at 5 Minutes Post-treatment |
1.01; 0.73 | — |
| SECONDARY Percentage Change in Pain Intensity Difference (% PID) at 10 Minutes Post-treatment |
4.83; 3.89 | — |
| SECONDARY Percentage Change in Pain Intensity Difference (% PID) at 15 Minutes Post-treatment |
12.38; 10.38 | — |
| SECONDARY Percentage Change in Pain Intensity Difference (% PID) at 30 Minutes Post-treatment |
29.72; 25.03 | — |
| SECONDARY Percentage Change in Pain Intensity Difference (% PID) at 45 Minutes Post-treatment |
44.84; 40.49 | — |
| SECONDARY Percentage Change in Pain Intensity Difference (% PID) at 60 Minutes Post-treatment |
52.61; 49.47 | — |
| SECONDARY Sum of Pain Intensity Difference at 30 Minutes Post-treatment (SPID30) |
2.54; 2.16 | <0.0001 sig |
| SECONDARY Sum of Pain Intensity Difference at 60 Minutes Post-treatment (SPID60) |
9.32; 8.50 | <0.0001 sig |
| SECONDARY Pain Relief (PR) Score at 5 Minutes Post-treatment |
0.11; 0.10 | 0.5575 |
| SECONDARY Pain Relief Score at 10 Minutes Post-treatment |
0.32; 0.26 | 0.0981 |
| SECONDARY Pain Relief Score at 15 Minutes Post-treatment |
0.68; 0.56 | 0.0443 sig |
| SECONDARY Pain Relief Score at 30 Minutes Post-treatment |
1.48; 1.22 | 0.0004 sig |
| SECONDARY Pain Relief Score at 45 Minutes Post-treatment |
2.14; 1.90 | 0.0001 sig |
| SECONDARY Pain Relief Score at 60 Minutes Post-treatment |
2.44; 2.27 | 0.0018 sig |
| SECONDARY Total Pain Relief at 60 Minutes (TOTPAR60) |
6.43; 5.70 | <0.0001 sig |
| SECONDARY Percent Total Pain Relief at 60 Minutes Posttreatment (%TOTPAR) |
40.11; 35.59 | — |
| SECONDARY Time to Any Pain Relief (APR) by Treatment - <= 5 Minutes |
55; 50 | 0.7012 |
| SECONDARY Time to Any Pain Relief (APR) by Treatment <=10 Minutes |
226; 219 | 0.6545 |
| SECONDARY Time to Any Pain Relief (APR) by Treatment <=15 Minutes |
515; 451 | 0.0407 sig |
| SECONDARY Time to Any Pain Relief (APR) by Treatment <=30 Minutes |
1004; 877 | 0.0007 sig |
| SECONDARY Time to Any Pain Relief (APR) by Treatment <=45 Minutes |
1217; 1150 | 0.0372 sig |
| SECONDARY Time to Any Pain Relief (APR) by Treatment <=60 Minutes |
1271; 1239 | 0.3099 |
| SECONDARY Time to Meaningful Pain Relief (MPR) by Treatment - <= 5 Minutes |
21; 26 | 0.5777 |
| SECONDARY Time to Meaningful Pain Relief (MPR) by Treatment <=10 Minutes |
88; 91 | 0.9567 |
| SECONDARY Time to Meaningful Pain Relief (MPR) by Treatment <=15 Minutes |
230; 212 | 0.4253 |
| SECONDARY Time to Meaningful Pain Relief (MPR) by Treatment <=30 Minutes |
613; 503 | 0.0038 sig |
| SECONDARY Time to Meaningful Pain Relief (MPR) by Treatment <=45 Minutes |
983; 864 | 0.0012 sig |
| SECONDARY Time to Meaningful Pain Relief (MPR) by Treatment <=60 Minutes |
1139; 1047 | 0.0074 sig |
| SECONDARY Use of Standard Rescue Medication |
39; 41 | 0.8444 |
| SECONDARY Medication Performance Assessment 30 Minutes Post-treatment |
49; 16; 125; 104; 378; 304 | <0.0001 sig |
| SECONDARY Medication Performance Assessment 60 Minutes Post-treatment |
160; 119; 371; 313; 508; 565 | <0.0001 sig |
| SECONDARY Breakthrough Pain Preference Questionnaire |
62; 46; 23; 12 | — |
| SECONDARY Patient Global Impression of Change (PGIC) at Visit 7- 1 Month After Open Label Treatment |
1.5; 0.6 | — |
| SECONDARY Patient Global Impression of Change (PGIC) at Visit 8- 2 Months After Open Label Treatment |
1.5; 0.8 | — |
| SECONDARY Patient Global Impression of Change (PGIC) at Visit 9- 3 Months After Open Label Treatment |
1.7; 0.8 | — |
| SECONDARY Patient Global Impression of Change (PGIC) Endpoint |
1.5; 0.9 | — |
| SECONDARY Clinician Global Impression of Change at Visit 7- 1 Month After Open Label Treatment |
1.4; 0.6 | — |
| SECONDARY Clinician Global Impression of Change (CGIC) at Visit 8- 2 Months After Open Label Treatment |
1.4; 0.7 | — |
| SECONDARY Clinician Global Impression of Change (CGIC) at Visit 9- 3 Months After Open Label Treatment |
1.6; 0.7 | — |
| SECONDARY Clinician Global Impression of Change (CGIC)Endpoint |
1.4; 0.7 | — |
Summary
Evaluate the efficacy of treatment with the fentanyl buccal tablet (FBT) compared with immediate release oxycodone treatment in alleviating breakthrough pain (BTP) in opioid tolerant patients with chronic pain.
Eligibility Criteria
Key Inclusion Criteria
- The patient has chronic pain of at least 3 months duration associated with any of the following conditions: diabetic peripheral neuropathy, postherpetic neuralgia, traumatic injury, complex regional pain syndrome, back pain, neck pain, fibromyalgia, chronic pancreatitis, osteoarthritis, rheumatoid arthritis, or cancer. Other chronic painful conditions may be evaluated for possible inclusion.
- The patient is currently using at least one of the following: at least 60 mg of oral morphine/day, or at least 25 mcg of transdermal fentanyl/hour, or at least 30 mg of oxycodone/day, or at least 8 mg of hydromorphone/day, or an equianalgesic dose of another opioid/day as ATC therapy for at least 7 days before administration of the first dose of study drug.
- The patient is willing to provide written informed consent, including a written opioid agreement form, to participate in this study.
- Women must be surgically sterile, 2 years postmenopausal, or, if of childbearing potential, using a medically accepted method of birth control and agree to continued use of this method for the duration of the study.
- Any patient with cancer should have a life expectancy of at least 3 months.
- The patient reports an average PI score, over the 24 hours prior to screening, of 6 or less (0=no pain through 10=pain as bad as you can imagine) for their chronic pain.
- The patient experiences, on average, at least 1 and less than 5 BTP episodes per day while taking ATC opioid therapy, and on average, the duration of each BTP episode is less than 4 hours during the screening period.
- The patient currently uses opioid therapy for alleviation of BTP episodes, occurring at the location of the chronic pain, and achieves at least partial relief.
- The patient must be willing and able to successfully self administer the study drug, comply with study restrictions, complete the electronic diary, and return to the clinic for scheduled study visits as specified in this protocol.
Key Exclusion Criteria
- The patient has uncontrolled or rapidly escalating pain as determined by the investigator or has pain uncontrolled by therapy that could adversely impact the safety of the patient or that could be compromised by treatment with study drug.
- The patient has a recent history (within 5 years) or current evidence of alcohol or other substance abuse.
- The patient has known or suspected hypersensitivities, allergies, or other contraindications to any ingredient in either study drug.
- The patient has a diagnosis of chronic headache or migraine as the primary painful condition with associated BTP.
- The patient has cardiopulmonary disease that would, in the opinion of the investigator, significantly increase the risk of treatment with potent synthetic opioids.
- The patient has medical or psychiatric disease that, in the opinion of the investigator, would compromise the patient's safety or collected data.
- The patient has suicidal ideation at screening or has a history of suicidal ideation within 1 year or history of suicide attempt within 2 years before screening, or a diagnosis of bipolar disorder or history of schizophrenia
- The patient is expected to have surgery during the study that will impact the patient's chronic pain and/or BTP.
- The patient has had therapy before study drug treatment that, in the opinion of the investigator, could alter pain or response to pain medication.
- The patient is pregnant or lactating.
- The patient has participated in a previous study with FBT.
- The patient has participated in a study involving an investigational drug in the prior 30 days.
- The patient is currently using FBT or oral transmucosal fentanyl citrate for BTP.
- The patient is currently using immediate-release oxycodone for BTP and is unwilling to undergo re-titration.
- The patient has received a monoamine oxidase inhibitor (MAOI) within 14 days before the first treatment with study drug.
- The patient has any other medical condition or i
Data sourced from ClinicalTrials.gov (NCT00813488). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.